Recent News

• 05.28.2025 - Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
• 05.28.2025 - Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
• 05.13.2025 - Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
• 05.13.2025 - Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
• 05.07.2025 - Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
• 04.30.2025 - Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
• 04.07.2025 - Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
• 04.07.2025 - Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

Recent Filings

• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 05.13.2025 - 8-K Current report
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2025 - EX-99.1 EX-99.1
• 04.30.2025 - DEFR14A Revised definitive proxy soliciting materials
• 04.25.2025 - 8-K Current report
• 04.22.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.22.2025 - ARS Annual Report to Security Holders